A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia

被引：0
|
作者：
Hafeez, M. [1 ]
Shaharyar, A. [1 ]
Zia, N. [1 ]
Rasheed, H. [1 ]
机构：
[1] King Edward Med Univ, Mayo Hosp, Lahore, Pakistan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18002
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
    Jeha, S
    Gaynon, PS
    Razzouk, BI
    Franklin, J
    Kadota, R
    Shen, V
    Litchtman-Jones, L
    Rytting, M
    Bomgaars, LR
    Rheingold, S
    Ritchey, K
    Albano, E
    Arceci, RJ
    Goldman, S
    Griffin, T
    Altman, A
    Gordon, B
    Steinherz, L
    Weitman, S
    Steinherz, P
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1917 - 1923
  • [22] A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia
    MA Weiss
    P Drullinsky
    P Maslak
    D Scheinberg
    DW Golde
    Leukemia, 1998, 12 : 865 - 868
  • [23] Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
    Advani, Anjali S.
    Li, Hongli
    Michaelis, Laura C.
    Medeiros, Bruno C.
    Liedtke, Michaela
    List, Alan F.
    O'Dwyer, Kristen
    Othus, Megan
    Erba, Harry P.
    Appelbaum, Frederick R.
    LEUKEMIA RESEARCH, 2018, 67 : 17 - 20
  • [24] TENIPOSIDE AND CYTARABINE COMBINATION CHEMOTHERAPY IN THE TREATMENT OF RELAPSED ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA
    SANZ, GF
    SANZ, MA
    RAFECAS, FJ
    MARTINEZ, JA
    MARTINARAGONES, G
    MARTY, ML
    CANCER TREATMENT REPORTS, 1986, 70 (11): : 1321 - 1323
  • [25] IDARUBICIN IN COMBINATION WITH INTERMEDIATE-DOSE CYTARABINE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE LEUKEMIAS
    CARELLA, AM
    PUNGOLINO, E
    PIATTI, G
    GAOZZA, E
    NATI, S
    SPRIANO, M
    GIORDANO, D
    DAMICO, T
    DAMASIO, E
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 43 (04) : 309 - 313
  • [26] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [27] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Norbert Vey
    Hagop Kantarjian
    Miloslav Beran
    Susan O'Brien
    Jorge Cortes
    Charles Koller
    Elihu Estey
    Investigational New Drugs, 1999, 17 : 89 - 95
  • [28] Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Shahswar, Rabia
    Beutel, Gernot
    Gabdoulline, Razif
    Schwarzer, Adrian
    Kloos, Arnold
    Koenecke, Christian
    Stadler, Michael
    Gohring, Gudrun
    Behrens, Yvonne Lisa
    Li, Zhixiong
    Dallmann, Louisa-Kristin
    Klement, Piroska
    Albert, Catherin
    Wichmann, Martin
    Alwie, Yasmine
    Benner, Axel
    Saadati, Maral
    Ganser, Arnold
    Thol, Felicitas
    Heuser, Michael
    HAEMATOLOGICA, 2024, 109 (01) : 72 - 83
  • [29] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Koller, C
    Estey, E
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 89 - 95
  • [30] Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia
    Miyagawa, Naoyuki
    Goto, Hiroaki
    Ogawa, Atsushi
    Kikuta, Atsushi
    Kosaka, Yoshiyuki
    Sekimizu, Masahiro
    Tomizawa, Daisuke
    Toyoda, Hidemi
    Hiramatsu, Hidefumi
    Hara, Junichi
    Mochizuki, Shinji
    Nakayama, Hideki
    Yoshimura, Kenichi
    Iijima-Yamashita, Yuka
    Sanada, Masashi
    Ogawa, Chitose
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (02) : 267 - 276
12345